Compare Meta Platforms Inc (META) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs TG Therapeutics Inc — how do they compare? Meta Platforms Inc trades at $642.86 (market cap $1.64T), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Meta Platforms Inc is far larger — about 198.5× TG Therapeutics Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| META | TGTX | |
|---|---|---|
Market Cap | $1.64T | $8.26B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $59.06 |
52-Week Low | $525.72 | $26.39 |
Enterprise Value | $1.65T | $8.50B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $643.78, down 0.35% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings of $10.44 EPS, beating expectations of $6.70, continuing a trend of earnings beats. Revenue reached $201.0B in 2025 with a net income margin of 30.08%. Recent news highlights the launch of Muse Spark AI model and a legal ruling requiring Meta to face a youth addiction lawsuit in Massachusetts.
The outlook remains positive with a consensus price target of $817.32, implying 27% upside. Key opportunities include AI innovation and revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst sentiment is strongly bullish with 79% buy ratings.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
